Get the Stockscreener App
74.38
2.32%
-1.77
After Hours:
74.38
Disc Medicine Inc stock is traded at $74.38, with a volume of 310.56K.
It is down -2.32% in the last 24 hours and up +5.07% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$76.15
Open:
$76.15
24h Volume:
310.56K
Relative Volume:
0.56
Market Cap:
$2.84B
Revenue:
-
Net Income/Loss:
$-241.60M
P/E Ratio:
-11.24
EPS:
-6.6167
Net Cash Flow:
$-201.34M
1W Performance:
-2.11%
1M Performance:
+5.07%
6M Performance:
+0.51%
1Y Performance:
+28.75%
1-Day Range:
$74.19
$77.48
1-Week Range:
$72.21
$77.48
52-Week Range:
$40.00
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
74.38 | 2.91B | 0 | -241.60M | -201.34M | -6.6167 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 123.26B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.94B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 53.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 39.58B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 35.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-11-25 | Resumed | Raymond James | Strong Buy |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - ACCESS Newswire
(IRON) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Truist Securities Initiates Coverage of Disc Medicine (IRON) with Buy Recommendation - MSN
Disc Medicine Stock Slumps After FDA Declines Approval For Inherited Disorder Drug Over Efficacy Concerns - Stocktwits
Lobbying Update: $50,000 of DISC MEDICINE lobbying was just disclosed - Quiver Quantitative
Putnam Investor News: If You Have Suffered Losses in Putnam Investment Management LLC, You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Disc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), ... - Caledonian Record
Cantor Fitzgerald reiterates Disc Medicine stock rating on pipeline catalysts - Investing.com
Disc Medicine Insider Sold Shares Worth $2,473,780, According to a Recent SEC Filing - Moomoo
Disc Medicine CEO John Quisel sells $2.47m in shares By Investing.com - Investing.com Nigeria
Form 4 Disc Medicine Inc For: 14 July By Investing.com - Investing.com South Africa
Disc Medicine CEO John Quisel sells $2.47m in shares - Investing.com
Disc Medicine (NASDAQ: IRON) CEO exercises options and sells 33,000 shares - Stock Titan
Form 144 Disc Medicine For: 13 July By Investing.com - Investing.com South Africa
Ironwood Pharmaceuticals (NASDAQ: IRON) plans 33,000-share sale via options exercise - Stock Titan
Disc Medicine Investor News: If You Have Suffered Losses in - GlobeNewswire
Price to earnings forward of Disc Medicine, Inc. – BOATS:IRON - TradingView
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - PR Newswire
Disc Medicine COO Jonathan Yu sells $8,250 in stock By Investing.com - Investing.com Nigeria
Form 4 Disc Medicine Inc For: 9 July By Investing.com - Investing.com Canada
Disc Medicine COO Jonathan Yu sells $8,250 in stock - Investing.com
Disc Medicine (IRON) COO trades 100 shares after option exercise under 10b5-1 plan - Stock Titan
Why Disc Medicine's Extended Hercules Credit Access Could Reshape IRON's Funding Flexibility Narrative - simplywall.st
Disc Medicine (IRON) H.C. Wainwright 27th Annual Global Investment Conference Summary - Quartr
Broker files Form 144 for 10,000 IRON shares (IRON) — option exercise sale - Stock Titan
IRON Q1 2026 Earnings: Narrower-than-expected loss highlights cost control amid clinical progressLong-Term Guidance - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Is Investigating Disc Medicine, Inc. (IRON) And Encourages Investors to Connect - The National Law Review
Disc Medicine (IRON) Could Be 67% Undervalued On Its $30 Million Loan Reset - Sahm
Did Disc Medicine’s Expanded Hercules Credit Access Just Shift IRON’s Funding Risk Profile? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Disc Medicine, Inc - The National Law Review
Disc Medicine’s chief legal officer sells $187,500 in stock - Investing.com UK
Disc Medicine COO Jonathan Yu sells $21,750 in company stock By Investing.com - Investing.com South Africa
Form 4 Disc Medicine Inc For: 30 June By Investing.com - Investing.com Nigeria
Disc Medicine’s chief legal officer sells $187,500 in stock By Investing.com - Investing.com Nigeria
Disc Medicine COO Jonathan Yu sells $21,750 in company stock - Investing.com
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
3.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):